Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : momo-T/FIF -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (11691)	9/24/2018 12:20:40 PM
From: Miljenko Zuanic	Read Replies (1) \| Respond to of 12215

In light of the today AMRN's Vascepa results and MH note in Forbes (https://www.forbes.com/sites/matthewherper/2018/09/24/in-blowout-amarins-fish-oil-derived-drug-dramatically-cuts-heart-risk-in-study/#3f152ef04f27), I am more convicted than ever that THR-beta agonist (2809 and 3196) are far more SUPERIOR (triglyceride, ApoB, Lp-a,...) than ANY Omega-3 product in CVD/NASH, TD-2 settings. My research (DD) 2-years ago were correct,..... while I did projected Vascepa failure (non-statistical reduction in MACE, not more than 10%..relative like Imrove-IT). So, I was wrong on VASCEPA! or, maybe not.....

To: tuck who wrote (11691)	9/24/2018 4:51:39 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 12215

switching subjects on you..... just did a search for patents relating to Arena's APD371. Know they're there, but they didn't seem to fall out immediately with relevant search terms. Knowing you, you may have been down this road? Only spent about 15 minutes, and only looked at applications, not issued. edit: searched for Arena and CB2, and CD119-related stuff popped out. But didn't find any CB2 agonists. Again, did not spend much time on it. Arena's small phase II (Crohn's) not generating ANY interest after hours.